Takeda sells Actos, the world's top-selling diabetespill, and Rozerem, a potential threat to sleep drugs like Lunesta and Ambien that so far hasn't taken off.
Next up in the company's pipeline is a promising diabetes pill--although Merck (nyse: MRK - news - people ) and Novartis (nyse: NVS - news - people ) are further ahead with similar drugs.
Merck has won approval from the U.S. Food and Drug Administration for its diabetespill Januvia, setting the stage for one of the most-watched drug marketing duels in years.